Unilife shares surge after the medical device company announces its latest pre-filled syringe supply deal with a major pharma player, this time Novartis.
Unilife (NSDQ:UNIS) shares are up some 12% today after the medical device company announced its latest supply deal with a pharmaceutical major.
Unilife inks another supply deal worth $40 million for its Unifill syringe, this time with Hikma Pharmaceuticals, sending share prices up sharply today.
Unilife (NSDQ:UNIS) inked another deal with a pharmaceutical company for its Unifill syringes, sending share prices up sharply today.
Unilife shares are up more than 24% this week on news of a deal with MedImmune, the biologics arm of pharmaceuticals giant AstraZeneca.
Unilife (NSDQ:UNIS) shares are up more than 24% this week on a supply deal for its wearable injectors it inked with MedImmune, the biologics division of pharma giant AstraZeneca (NYSE:AZN).
Endo Health Solutions begins work on a $1.6 billion buyout of Paladin Labs and announces Q3 adjusted EPS that blows away analysts' estimates.
There are big things afoot at Endo Health Solutions (NSDQ:ENDP), which announced plans to pick up specialty pharmaceuticals maker Paladin Labs in a deal valued at $1.6 billion.
Panelists at this year's Transcatheter Cardiovascular Therapeutics symposium debate whether left atrial appendage occlusion device makers can compete against anti-coagulant drug makers, which have long held a coveted spot as the gold standard in stroke prevention for patients with atrial fibrillation.
Federal healthcare regulators warn a slew of foreign and domestic companies who claim to sell products that mitigate, treat, cure or prevent diabetes.
The FDA this week warned consumers about a slew of companies making unverified and potentially dangerous claims about products marketed to patients with diabetes.
No less than 15 companies were accused of making unapproved claims and the FDA is "taking action to remove from the market illegal products," according to the notice.
Massachusetts-based Covidien officially becomes a pure-play medical device company after executing the spinout of its pharmaceuticals business into independently operated Mallinckrodt plc, which today began trading on the New York Stock Exchange.